Cargando…

Insights on prospects of nano-siRNA based approaches in treatment of Cancer

siRNA interference, commonly referred to as gene silence, is a biological mechanism that inhibits gene expression in disorders such as cancer. It may enhance the precision, efficacy, and stability of medicines, especially genetic therapies to some extent. However, obstacles such as the delivery of o...

Descripción completa

Detalles Bibliográficos
Autores principales: Goyal, Rajat, Chopra, Hitesh, singh, Inderbir, Dua, Kamal, Gautam, Rupesh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452808/
https://www.ncbi.nlm.nih.gov/pubmed/36091772
http://dx.doi.org/10.3389/fphar.2022.985670
_version_ 1784784995487842304
author Goyal, Rajat
Chopra, Hitesh
singh, Inderbir
Dua, Kamal
Gautam, Rupesh K.
author_facet Goyal, Rajat
Chopra, Hitesh
singh, Inderbir
Dua, Kamal
Gautam, Rupesh K.
author_sort Goyal, Rajat
collection PubMed
description siRNA interference, commonly referred to as gene silence, is a biological mechanism that inhibits gene expression in disorders such as cancer. It may enhance the precision, efficacy, and stability of medicines, especially genetic therapies to some extent. However, obstacles such as the delivery of oligonucleotide drugs to inaccessible areas of the body and the prevalence of severe side effects must be overcome. To maximize their potential, it is thus essential to optimize their distribution to target locations and limit their toxicity to healthy cells. The action of siRNA may be harnessed to delete a similar segment of mRNA that encodes a protein that causes sickness. The absence of an efficient delivery mechanism that shields siRNA from nuclease degradation, delivers it to cancer cells and releases it into the cytoplasm of specific cancer cells without causing side effects is currently the greatest obstacle to the practical implementation of siRNA therapy. This article focuses on combinations of siRNA with chemotherapeutic drug delivery systems for the treatment of cancer and gives an overview of several nanocarrier formulations in both research and clinical applications.
format Online
Article
Text
id pubmed-9452808
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94528082022-09-09 Insights on prospects of nano-siRNA based approaches in treatment of Cancer Goyal, Rajat Chopra, Hitesh singh, Inderbir Dua, Kamal Gautam, Rupesh K. Front Pharmacol Pharmacology siRNA interference, commonly referred to as gene silence, is a biological mechanism that inhibits gene expression in disorders such as cancer. It may enhance the precision, efficacy, and stability of medicines, especially genetic therapies to some extent. However, obstacles such as the delivery of oligonucleotide drugs to inaccessible areas of the body and the prevalence of severe side effects must be overcome. To maximize their potential, it is thus essential to optimize their distribution to target locations and limit their toxicity to healthy cells. The action of siRNA may be harnessed to delete a similar segment of mRNA that encodes a protein that causes sickness. The absence of an efficient delivery mechanism that shields siRNA from nuclease degradation, delivers it to cancer cells and releases it into the cytoplasm of specific cancer cells without causing side effects is currently the greatest obstacle to the practical implementation of siRNA therapy. This article focuses on combinations of siRNA with chemotherapeutic drug delivery systems for the treatment of cancer and gives an overview of several nanocarrier formulations in both research and clinical applications. Frontiers Media S.A. 2022-08-25 /pmc/articles/PMC9452808/ /pubmed/36091772 http://dx.doi.org/10.3389/fphar.2022.985670 Text en Copyright © 2022 Goyal, Chopra, singh, Dua and Gautam. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Goyal, Rajat
Chopra, Hitesh
singh, Inderbir
Dua, Kamal
Gautam, Rupesh K.
Insights on prospects of nano-siRNA based approaches in treatment of Cancer
title Insights on prospects of nano-siRNA based approaches in treatment of Cancer
title_full Insights on prospects of nano-siRNA based approaches in treatment of Cancer
title_fullStr Insights on prospects of nano-siRNA based approaches in treatment of Cancer
title_full_unstemmed Insights on prospects of nano-siRNA based approaches in treatment of Cancer
title_short Insights on prospects of nano-siRNA based approaches in treatment of Cancer
title_sort insights on prospects of nano-sirna based approaches in treatment of cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452808/
https://www.ncbi.nlm.nih.gov/pubmed/36091772
http://dx.doi.org/10.3389/fphar.2022.985670
work_keys_str_mv AT goyalrajat insightsonprospectsofnanosirnabasedapproachesintreatmentofcancer
AT choprahitesh insightsonprospectsofnanosirnabasedapproachesintreatmentofcancer
AT singhinderbir insightsonprospectsofnanosirnabasedapproachesintreatmentofcancer
AT duakamal insightsonprospectsofnanosirnabasedapproachesintreatmentofcancer
AT gautamrupeshk insightsonprospectsofnanosirnabasedapproachesintreatmentofcancer